⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKBA News
Akebia Therapeutics, Inc.
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
globenewswire.com
AKBA
Advancements in CKD Care: How New Therapies from AstraZeneca, Johnson & Johnson, Novartis, Bayer, and Amgen Are Changing the Landscape
globenewswire.com
AMGN
AZN
JNJ
NVS
ABBV
AKBA
ARDX
CHNR
LLY
FGEN
GILD
GSK
NVO
PFE
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
globenewswire.com
AKBA
Form 8-K
sec.gov
AKBA